{"title": "Hapalindoles from the Cyanobacterium Hapalosiphon sp. Inhibit T Cell Proliferation", "author": "Chilczuk; Tomasz; Steinborn; Carmen; Breinlinger; Steffen; Zimmermann-Klemd; Amy Marisa; Huber; Roman; Enke; Heike; Dan; Niedermeyer; Timo Horst Johannes; Gr\u00fcndemann; Carsten", "url": null, "hostname": null, "description": "Novel immunomodulating agents are currently sought after for the treatment of autoimmune diseases and cancers. In this context, a screening campaign of a collection of 575 cyanobacteria extracts for immunomodulatory effects has been conducted. The screening resulted in several active extracts. Here we report the results of subsequent studies on an extract from the cyanobacterium; Hapalosiphon; sp. CBT1235. We identified 5 hapalindoles as the compounds responsible for the observed immunomodulatory effect. These indole alkaloids are produced by several strains of the cyanobacterial family Hapalosiphonaceae. They are known for their anti-infective, cytotoxic, and other bioactivities. Modulation of the activity of human immune cells has not yet been described. The immunomodulatory activity of the hapalindoles was characterized; in vitro; using flow cytometry-based measurements of T cell proliferation after carboxyfluorescein diacetate succinimidyl ester staining, and apoptosis and necrosis induction after annexin V/propidium iodide staining. The most potent compound, hapalindole A, reduced T cell proliferation with an IC; 50; of 1.56 \u00b5M, while relevant levels of apoptosis were measurable only at 10-fold higher concentrations. Hapalindole A-formamide and hapalindole J-formamide, isolated for the first time from a natural source, had much lower activity than the nonformylated derivatives while, at the same time, being less selective for antiproliferative over apoptotic effects.", "sitename": "Hapalindoles from the Cyanobacterium Hapalosiphon sp. Inhibit T Cell Proliferation", "date": "2021-12-17", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Chilczuk, Tomasz and Steinborn, Carmen and Breinlinger, Steffen and Zimmermann-Klemd, Amy Marisa and Huber, Roman and Enke, Heike and Enke, Dan and Niedermeyer, Timo Horst Johannes and Gr\u00fcndemann, Carsten. (2020) Hapalindoles from the Cyanobacterium Hapalosiphon sp. Inhibit T Cell Proliferation. Planta medica, 86 (2). pp. 96-103.\nFull text not available from this repository.\nOfficial URL:\n[https://edoc.unibas.ch/75695/](https://edoc.unibas.ch/75695/)\nDownloads:\n[Statistics Overview](/cgi/stats/report/eprint/75695)\nAbstract\nNovel immunomodulating agents are currently sought after for the treatment of autoimmune diseases and cancers. In this context, a screening campaign of a collection of 575 cyanobacteria extracts for immunomodulatory effects has been conducted. The screening resulted in several active extracts. Here we report the results of subsequent studies on an extract from the cyanobacterium; Hapalosiphon; sp. CBT1235. We identified 5 hapalindoles as the compounds responsible for the observed immunomodulatory effect. These indole alkaloids are produced by several strains of the cyanobacterial family Hapalosiphonaceae. They are known for their anti-infective, cytotoxic, and other bioactivities. Modulation of the activity of human immune cells has not yet been described. The immunomodulatory activity of the hapalindoles was characterized; in vitro; using flow cytometry-based measurements of T cell proliferation after carboxyfluorescein diacetate succinimidyl ester staining, and apoptosis and necrosis induction after annexin V/propidium iodide staining. The most potent compound, hapalindole A, reduced T cell proliferation with an IC; 50; of 1.56 \u00b5M, while relevant levels of apoptosis were measurable only at 10-fold higher concentrations. Hapalindole A-formamide and hapalindole J-formamide, isolated for the first time from a natural source, had much lower activity than the nonformylated derivatives while, at the same time, being less selective for antiproliferative over apoptotic effects.\n|Faculties and Departments:||05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Translational Complementary Medicine (Gr\u00fcndemann)|\n|UniBasel Contributors:|\n- doi:\n[10.1055/a-1045-5178](http://dx.doi.org/10.1055/a-1045-5178)\n- pmid:\n[31777053](http://www.ncbi.nlm.nih.gov/pubmed/31777053?otool=unibaslib)\nRepository Staff Only:\n[item control page](https://edoc.unibas.ch/cgi/users/home?screen=EPrint::View&eprintid=75695)", "language": null, "image": null, "pagetype": null, "links": ["https://www.unibas.ch/en", "https://edoc.unibas.ch/", "https://edoc.unibas.ch/", "https://edoc.unibas.ch/policies.html", "https://ub.unibas.ch/de/digitale-dienste/edoc/", "/cgi/stats/report", "mailto:openaccess@unibas.ch?subject=%5Bedoc%5D", "https://edoc.unibas.ch/cgi/users/home", "https://edoc.unibas.ch/75695/", "/cgi/stats/report/eprint/75695", "/view/contributors_basel_id/159823.html", "/view/contributors_basel_id/180394.html", "http://dx.doi.org/10.1055/a-1045-5178", "http://www.ncbi.nlm.nih.gov/pubmed/31777053?otool=unibaslib", "https://edoc.unibas.ch/cgi/users/home?screen=EPrint::View&eprintid=75695", "http://eprints.org/software/", "http://www.ecs.soton.ac.uk/"]}